

# OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% Storage and Preparation Requirements

The following information is provided to help integrate OMIDRIA into your operating routine.

## OMIDRIA DILUTION AND STORAGE<sup>1</sup>

### Prior to dilution

- Store at 20°C to 25°C (68°F to 77°F)
- Protect from light


### Easy to integrate into routine operating procedures

- Add preoperatively to irrigating solution

**Do not use if the solution is cloudy or contains particulate matter.**

### After dilution, product can be stored:

**Up to 4 hours**  
at room temperature




**Up to 24 hours**  
if refrigerated



## PREPARATION AND ADMINISTRATION OF OMIDRIA

- Add preoperatively to irrigating solution
  - One 4-mL single-patient-use vial to 500 mL ophthalmic irrigating solution
  - No other preparation required
  - Can be added to irrigating solution in the surgical suite
  - No calculations—preparation is the same for every patient
- Additionally, you may place an OMIDRIA container sticker, which is available from your OMIDRIA sales representative, on the container of diluted irrigating solution



**OMIDRIA**  
(phenylephrine and ketorolac  
intraocular solution)  
1% / 0.3%


Name: \_\_\_\_\_

DOB: \_\_\_\_\_ Eye:  OS (Left)  OD (Right)

2018-054

### IMPORTANT SAFETY INFORMATION

OMIDRIA® must be added to irrigating solution prior to use and is contraindicated in patients with known hypersensitivity to any of its ingredients. Systemic exposure to phenylephrine may cause elevations in blood pressure. The most commonly reported ocular adverse reactions at ≥2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.






# Less stress, pure success... in your O.R. day<sup>2</sup>

Choose FDA-approved OMIDRIA to experience **less stress<sup>2</sup>** in your O.R. day and **deliver better outcomes** for your patients

OMIDRIA is:

- The first and only NSAID-containing product approved by FDA for intraocular use
- Preservative-free and bisulfite-free<sup>1</sup>
- Provides greater iris tone and pupil stability for better visualization of the operative field and safe surgical procedures<sup>1</sup>
- Manufactured according to FDA Good Manufacturing Practices (GMP)—eliminates the safety, accreditation, and liability risks associated with compounded products

**OMIDRIA is the only FDA-approved product that  
delivers an NSAID intracamerally**



OMIDRIA is covered  
and paid by **100% of  
Medicare Administrative  
Contractors (MACs)** across  
all **50 states** and Puerto Rico  
in the ambulatory surgery  
center (ASC) setting.<sup>3</sup>

OMIDRIA has a  
unique billing code

**J1097<sup>4</sup>**

**1 billing unit = 1 mL;  
one standard 4-mL vial =  
4 units**

**For more information about OMIDRIA, please call 1-844-OMEROS1 (1-844-663-7671).  
Please see Full Prescribing Information at [www.omidria.com/prescribinginformation](http://www.omidria.com/prescribinginformation).**

Based on currently available information and subject to change. Omeros does not guarantee coverage or reimbursement. Medicare Part B patients at ambulatory surgery centers (ASCs) have a 20% co-pay obligation. Approximately 90% of Medicare Part B patients have some form of supplemental/secondary insurance that covers co-payments.<sup>5</sup>

**References:** **1.** OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. **2.** Omeros survey data on file. **3.** Medicare program: changes to hospital outpatient prospective payment and ambulatory surgical center payment systems and quality reporting programs. Fed Regist. 2018(83):58818-59179. **4.** HCPCS quarterly update. CMS.gov. Available at: <https://www.cms.gov/medicare/coding/hcpcsreleasecodesets/hcpcs-quarterly-update.html>. Accessed August 9, 2019. **5.** Kaiser Family Foundation analysis of the CMS Medicare Current Beneficiary Survey Cost and Use File, 2010.



OMEROS®, the OMEROS logo®, OMIDRIA®, and the OMIDRIA logo® are registered trademarks of Omeros Corporation.

© Omeros Corporation 2019, all rights reserved. US-OM-2000178



**OMIDRIA®**  
(phenylephrine and ketorolac  
intraocular solution)  
1% / 0.3%